Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain
Torres, Antoni ![ORCID Identifier](/img/uab/orcid.ico)
(Hospital Clínic i Provincial de Barcelona)
Bassetti, Matteo ![ORCID Identifier](/img/uab/orcid.ico)
(Santa Maria della Misericordia University Hospital, Udine)
Welte, Tobias ![ORCID Identifier](/img/uab/orcid.ico)
(Medizinische Hochschule Hannover)
Rivolo, Simone (Evidera, London)
Remak, Edit (Evidera, Budapest)
Peral, Carmen (Pfizer, Madrid)
Charbonneau, Claudie (Pfizer, Paris)
Hammond, Jennifer (Pfizer)
Ansari, Wajeeha (Pfizer, New York)
Grau, Santiago
(Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Date: |
2020 |
Abstract: |
Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal. Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alternative to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III-IV) from the perspective of the Spanish National Health System (NHS). Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated patients discharged early (PDE) (30. 6% vs. 26. 1%) while decreasing initial antibiotic failures (3. 8% vs. 7. 6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1. 2%) and significantly increased PDE (32. 1% vs. 24. 6%). CFT resulted in cost-saving vs. levofloxacin, due lower initial antibiotic therapy costs and increased PDE (30. 6% vs. 14. 9%). Moxifloxacin and co-amoxiclav early response rate of 53. 63% and 54. 24% resulted in cost neutrality vs. CFT, with direct comparison hampered by the significantly different early response criteria utilized in the literature. Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hospitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower total costs. |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. ![Creative Commons](/img/licenses/by-nc-nd.ico) |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Published in: |
Journal of Medical Economics, Vol. 23 Núm. 2 (january 2020) , p. 148-155, ISSN 1941-837X |
DOI: 10.1080/13696998.2019.1688819
PMID: 31686550
The record appears in these collections:
Articles >
Research articlesArticles >
Published articles
Record created 2020-06-03, last modified 2024-07-24